Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.42 |
| ▸ | MAT2A | P31153 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5412758 | 0.83 | KCNH2 (0.50) | KCNH2MAT2AKDM4ENPC1LMNA | |
| SCHEMBL5407423 | 0.79 | HSD11B1 (0.38) | NFE2L2KCNH2MAT2A | |
| SCHEMBL15050564 | 0.78 | NFE2L2 (0.54) | NFE2L2KCNH2MAT2AACHEIKBKB | |
| SCHEMBL12186097 | 0.78 | NFE2L2 (0.54) | NFE2L2KCNH2MAT2AACHEIKBKB | |
| SCHEMBL5254562 | 0.75 | NFE2L2 (0.50) | NFE2L2KCNH2MAT2AACHEIKBKB | |
| SCHEMBL5414214 | 0.74 | CES2 (0.32) | NFE2L2CES2CES1 | |
| SCHEMBL1461201 | 0.74 | NFE2L2 (0.44) | NFE2L2KCNH2MAT2AACHEIKBKB | |
| SCHEMBL12656511 | 0.71 | ACHE (0.46) | NFE2L2KCNH2MAT2AACHEABCG2 | |
| SCHEMBL95708 | 0.71 | ERN1 (0.50) | NFE2L2KCNH2MAT2AIKBKBCES2 | |
| SCHEMBL129124 | 0.71 | NFE2L2 (0.46) | NFE2L2KCNH2MAT2AIKBKBCES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | claimed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | claimed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | claimed |
| US-6723743-B1 | TREATING PATIENT SUFFERING FROM RHEUMATOID ARTHRITIS, PSORIASIS, BRONCHIAL ASTHMA, ALZHEIMER'S DISEASE, MYOCARDIAL INFARCTION OR ATHEROSCLEROSIS | NEUROGEN CORPORATION | 2004-04-20 | — | — | US | claimed |
| WO-2023246009-A1 | OLEFIN POLYMERIZATION METALLOCENE CATALYST COMPOSITION, PREPARATION THEREOF AND USE THEREOF | 中国石油天然气股份有限公司 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023240961-A1 | ETHYLENE-PROPYLENE COPOLYMERIZATION CATALYST COMPOSITION, AND PREPARATION AND USE THEREOF | 中国石油天然气股份有限公司 | 2023-12-21 | — | — | WO | disclosed |
| EP-4273147-A1 | SUBSTITUTED SPIROLACTAMS, SALTS THEREOF AND THEIR USE AS HERBICIDALLY ACTIVE SUBSTANCES | Bayer Aktiengesellschaft (DE) | 2023-11-08 | — | — | EP | disclosed |
| CN-115867534-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115803025-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2023-03-14 | — | — | CN | disclosed |
| CN-114174263-A | Non-lysosomal glucosylceramidase inhibitors and uses thereof | 阿勒克图治疗公司 | 2022-03-11 | — | — | CN | disclosed |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | PETROCHINA COMPANY LIMITED (CN) | 2020-02-27 | — | — | US | disclosed |
| EP-1366026-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-03 | — | — | EP | disclosed |
| US-20030187042-A1 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6613493-B2 | Formed by nitrating a polyvinylphenol or a novalak and reacting the the hydroxy group with with a halide comprising an acid labile protecting group, such as 2-(1-bromoethyl)-1,3-difluorobenzene | HYNIX SEMICONDUCTOR INC (KR) | 2003-09-02 | — | — | US | disclosed |
| US-20030149087-A1 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2003-08-07 | — | — | US | disclosed |
| WO-2003015777-A1 | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003015771-A1 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | LION BIOSCIENCE AG (DE) | 2003-02-27 | — | — | WO | disclosed |
| US-20030013036-A1 | Photoresist polymer and composition having nitro groups | HYNIX SEMICONDUCTOR INC. (KR) | 2003-01-16 | — | — | US | disclosed |
| WO-2002024663-A2 | PYRIMIDINE COMPOUNDS AND THEIR USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149087-A1 | NR1H4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | NFE2L2 408/4885KCNH2 2798/4885MAT2A 3287/4885 |
| US-20030187042-A1 | NR1H4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | NFE2L2 386/4885KCNH2 2774/4885MAT2A 3224/4885 |
| US-20200062874-A1 | METALLOCENE COMPLEX WITH A HETEROATOM-CONTAINING PI-LIGAND AND PREPARATION METHOD THEREFOR, CATALYST SYSTEM CONTAINING THE SAME AND USE THEREOF | ORC3, ORMDL3, OR51E2 | NFE2L2 143/4885KCNH2 2787/4885MAT2A 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.